G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT
Authors:
- 28 February 2011
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (1) , 73-81
Abstract
In G-CSF-mobilized hematopoietic SCT (HSCT), natural killer (NK) cells have a critical role in GVHD and GVL effects. However, regulation of NK cell response to G-CSF remains unclear. This study assayed G-CSF effects in both HSCT donors and NK-92MI cells. The donors who received G-CSF had significantly decreased NK cell cytotoxicity. Levels of phosphatidylinositol 3-kinase (PI3K) and phosphorylated (p)-Akt, but not mammalian target of rapamycin (mTOR), were downregulated in NK cells from G-CSF-injected donors. G-CSF also decreased cytotoxicity without affecting viability and NF-κB of NK-92MI cells. PI3K and p-ERK expression were also decreased in G-CSF-treated NK-92MI cells, and their inhibitors, wortmannin and PD98059, respectively, both enhanced the downregulation of cytotoxicity. These effects were accompanied by decreased expression of a cytotoxicity-related gene, triosephosphate isomerase (TPI). Wortmannin, but not PD98059, enhanced the downregulation of TPI in G-CSF-treated NK-92MI cells, indicating a correlation between PI3K and TPI. We conclude that G-CSF-impaired NK cell cytotoxicity may accompany PI3K/Akt signaling. The effect is transient and NK cells may recover after G-CSF clearance, suggesting that G-CSF-mobilized HSCT may benefit both acute GVHD prevention and late-phase GVL promotion in HSCT recipients.Keywords
This publication has 34 references indexed in Scilit:
- Functional regulation and proteomic characterization of human natural killer cells through recombinant human granulocyte-colony stimulating factor treatmentProteomics – Clinical Applications, 2009
- Allosteric LFA-1 Inhibitors Modulate Natural Killer Cell FunctionMolecular Pharmacology, 2009
- Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse RatesTransplantation and Cellular Therapy, 2008
- Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant DiseasesJAMA, 2008
- NK/NKT Cells and AgingInternational Journal of Gerontology, 2007
- Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cellsCell Research, 2006
- KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantationMolecular Immunology, 2005
- A potential therapeutic role for small nonpeptidyl compounds that mimic human granulocyte colony-stimulating factorBlood, 2004
- Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan ConditioningActa Oncologica, 2000
- Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignanciesBone Marrow Transplantation, 1998